Sciomics‘ Impact on Proteomic Research

Patents

Please find below selected patents with contribution of our scioDiscover microarray platform.

Selected Patents

WO2021175863A1: Method for diagnosis and/or prognosis of liver disease progression and risk of hepatocellular carcinoma and discovery of therapeutic compounds and targets to treat liver disease and cancer
WO2021162554A1: Means and methods for determining mesenchymal stromal cell properties.
US20210137912A1: s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid for use in medicine
EP2536844B1, US9551035B2: Means and methods for diagnosing pancreatic cancer
EP2718720B1, US9678075B2: Prediction of recurrence for bladder cancer by a protein signature in tissue samples

Subcategories

Proteomics Research Blog

At Sciomics, we are dedicated to advancing healthcare through proteomics research. We are collaborating with research groups and big pharma, alongside our in-house biomarker research initiatives. To make this research more accessible to you, we have launched the Sciomics science blog!
Publications

Find peer-reviewed scientific publications on biomedical studies supported by our antibody microarray platform, scientific publications on the platform itself, information on poster presentations at international conferences and patents supported by Sciomics services.

scioPhospho: protein profiling and phosphorylation status

Our scioPhospho analysis combines protein expression profiling using scioDiscover with analysis of the corresponding protein's phosphorylation status. More than 1,400 proteins are analyzed in parallel, covering key pathways in diseases such as cancer, neurological disorders and organ failure. This combination provides a comprehensive overview of signaling events and pathway activity…

scioUbi: protein profiling and ubiquitination status

Protein & ubiquitination profiling scioUbi is a high-content protein expression and ubiquitination level analysis. With scioUbi you can analyse more than 1,400 proteins in a single assay. Features Screen…

scioDiscover - Protein Profiling on the Expression Level

Knowledge about protein expression levels is of utmost importance to predict toxic effects, estimate adverse effects of drug candidates and to identify new drug targets. Sciomics has a highly optimised…

scioCD - Cell Surface Marker and Cytokine Profiling

Characterize Your Cell Type! Cell Composition Analysis in Tissue Samples CD-Marker Expression Profiles Increased Throughput at High Sensitivity Levels High Reproducibility Our scioCD profiling service covers 349 different…

scioCyto : Cytokine Profiling

scioCyto : Cytokine profiling scioCyto is a high-content analysis service for multiplex cytokine and chemokine profiling on protein level. A great variety of samples such as plasma, tissue, cells or cell…

New Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

| September 2023 | New Article: Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Sciomics supported this study by scioCyto serum analysis in a mouse cancer model.

Taylor, J., Uhl, L., Moll, I. et al. Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia. Nat Cancer 4, 1544–1560 (2023).

New Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

| July 2023 | New Article: Fiedler et al. developed a novel methodology for vitamin B6 diagnostics. We supported the project by the production of custom antibody microarray targeting signature human PLP-DE and testing respective samples.

Fiedler et al. Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes via PLP Cofactor Mimics (2023) ACS Chem Biol.

New Article | Microbiota Influences Chemotherapy in Pancreatic Cancer

| February 2023 | New Article: In the study Tintelnot et al. identified a microbiota-derived metabolite that has clinical implications in the treatment of pancreatic cancer. Sciomics supported the authors by a protein profiling study of tumours derived from a mouse model upon treatment with 3-IAA and Firinox.

Tintelnot et al. Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer. Nature 615, 168-174 (2023)

New Article | Predicting a severe Covid-19 disease

| April 2023 | New Article: In a protein biomarker development project initiated by Sciomics, we have identified protein biomarker panels predicting development of a severe Covid.19 disease.

Hufnagel K., Fathi A. et al. Discovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease. Communications Medicine 3,51 (2023)

New Sciomics Proteomics Research Blog has Launched!

Sciomics Protomics Research Blog

At Sciomics, we are dedicated to advancing healthcare through proteomics research. We are collaborating with research groups and big pharma, alongside our in-house biomarker research initiatives. To make this research more accessible to you, we are launching the new Sciomics science blog!

The first study we will feature was published this year in a journal in the Nature publishing group. It's a topic that affects us all. Any guesses? Stay tuned!

Tara Sigdel, PhD

Associate Professor, Department of Surgery, University of California San Francisco

"We collaborated with Sciomics GmbH in Germany to analyze proteomics data from blood samples of kidney transplant recipients and liver perfusates during normothermic machine perfusion. Throughout the process, Sciomics provided exceptional support, ensuring timely data delivery and valuable assistance with data analysis. Their expertise and commitment have been instrumental in advancing our research, and we are currently using their data in multiple manuscript submissions. I highly recommend Sciomics for their reliable service and expertise in proteomics."

Product: scioDiscover

Dr. Matthew Wright

Chief Scientific Officer, Kinarus Therapeutics AG, Basel, Switzerland

"We are a small biotech company without our own wet labs. Sciomics recommended a UK CRO that performed cell culture experiments for our studies. Sciomics seamlessly coordinated the transfer of the biologic materials to their facility and performed the scioCD panel to characterize cell surface markers and cytokines in cell lines treated with our small molecule drug candidates. The Sciomics data were instrumental in supporting our IP protection strategy. Their advice was very helpful and they worked with us to extract the most out of the data. We are very satisfied and highly recommend the Sciomics platform and the team."

Product: scioCD

Patents

Selected Patents

Subcategories

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioUbi: protein profiling and ubiquitination status

scioDiscover - Protein Profiling on the Expression Level

scioCD - Cell Surface Marker and Cytokine Profiling

scioCyto : Cytokine Profiling

COVID-19 related activities and services

News

New Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

New Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

New Article | Microbiota Influences Chemotherapy in Pancreatic Cancer

New Article | Predicting a severe Covid-19 disease

New Sciomics Proteomics Research Blog has Launched!

Testimonials

Beadcrumbs

Selected Patents

Subcategories

Our service portfolio

scioPhospho: protein profiling and phosphorylation status

scioUbi: protein profiling and ubiquitination status

scioDiscover - Protein Profiling on the Expression Level

scioCD - Cell Surface Marker and Cytokine Profiling

scioCyto : Cytokine Profiling

COVID-19 related activities and services

News

New Article | Endothelial Notch1 signaling in white adipose tissue promotes cancer cachexia

New Article | Rapid Diagnostic Platform for Personalized Vitamin B6 Detection in Erythrocytes

New Article | Microbiota Influences Chemotherapy in Pancreatic Cancer

New Article | Predicting a severe Covid-19 disease

New Sciomics Proteomics Research Blog has Launched!

Testimonials